William Blair Increases Earnings Estimates for Cabaletta Bio

Cabaletta Bio, Inc. (NASDAQ:CABA) – Analysts at William Blair increased their Q1 2025 earnings per share (EPS) estimates for shares of Cabaletta Bio in a research note issued to investors on Tuesday, April 1st. William Blair analyst S. Corwin now expects that the company will earn ($0.68) per share for the quarter, up from their previous forecast of ($0.72). The consensus estimate for Cabaletta Bio’s current full-year earnings is ($2.34) per share. William Blair also issued estimates for Cabaletta Bio’s Q2 2025 earnings at ($0.73) EPS, Q3 2025 earnings at ($0.72) EPS, Q4 2025 earnings at ($0.69) EPS, FY2025 earnings at ($2.82) EPS, Q4 2026 earnings at ($0.74) EPS and FY2026 earnings at ($2.91) EPS.

Cabaletta Bio (NASDAQ:CABA) last issued its quarterly earnings data on Monday, March 31st. The company reported ($0.65) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.65).

Several other analysts also recently issued reports on CABA. Evercore ISI downgraded shares of Cabaletta Bio from an “outperform” rating to an “inline” rating and decreased their price objective for the stock from $15.00 to $6.00 in a research note on Friday, December 20th. Wells Fargo & Company dropped their price objective on shares of Cabaletta Bio from $6.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Tuesday. Guggenheim reissued a “buy” rating and set a $23.00 price target on shares of Cabaletta Bio in a research report on Tuesday. HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of Cabaletta Bio in a research note on Tuesday. Finally, UBS Group cut their target price on Cabaletta Bio from $10.00 to $7.00 and set a “buy” rating on the stock in a research report on Tuesday. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Cabaletta Bio presently has an average rating of “Buy” and an average price target of $21.00.

Cabaletta Bio Price Performance

Shares of CABA stock opened at $1.11 on Friday. The stock’s 50 day simple moving average is $1.98 and its two-hundred day simple moving average is $2.89. The company has a market cap of $56.32 million, a PE ratio of -0.52 and a beta of 2.44. Cabaletta Bio has a 1 year low of $1.08 and a 1 year high of $19.04.

Institutional Investors Weigh In On Cabaletta Bio

Several hedge funds have recently modified their holdings of CABA. T. Rowe Price Investment Management Inc. boosted its holdings in Cabaletta Bio by 10.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,074,006 shares of the company’s stock worth $9,248,000 after buying an additional 400,282 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its stake in shares of Cabaletta Bio by 19.7% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,634,473 shares of the company’s stock valued at $8,250,000 after acquiring an additional 597,828 shares during the period. Point72 Asset Management L.P. boosted its position in shares of Cabaletta Bio by 89.7% during the fourth quarter. Point72 Asset Management L.P. now owns 1,265,882 shares of the company’s stock worth $2,874,000 after buying an additional 598,607 shares during the period. Geode Capital Management LLC increased its stake in Cabaletta Bio by 1.5% during the fourth quarter. Geode Capital Management LLC now owns 1,110,702 shares of the company’s stock worth $2,522,000 after purchasing an additional 16,058 shares during the period. Finally, Two Sigma Advisers LP grew its stake in shares of Cabaletta Bio by 195.8% in the fourth quarter. Two Sigma Advisers LP now owns 831,900 shares of the company’s stock worth $1,888,000 after acquiring an additional 550,700 shares in the last quarter.

About Cabaletta Bio

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.